多发性硬化正处于检查点: 推进该项目
BC Smith, JL Williams - 中国神经再生研究(英文版), 2025 - sjzsyj.com.cn
… likely reduce the activation of any exposed … ) Association of early progression independent
of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis…
of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis…
MicroRNAs 作为实验性自身免疫性脑脊髓炎多发性硬化症模型的疾病进展生物标志物和治疗靶标
B Martinez, PV Peplow - 中国神经再生研究(英文版), 2020 - sjzsyj.com.cn
… function (increasing disability) (National Multiple Sclerosis Society). … Ocrelizumab and
siponimod are the only medications … and reduced N-acetyl aspartate in chronic multiple sclerosis …
siponimod are the only medications … and reduced N-acetyl aspartate in chronic multiple sclerosis …
EB 病毒在多发性硬化中的作用: 从分子病理生理学到体内成像
… Multiple sclerosis (MS) is a disease of the central nervous … -CD20 agents such as rituximab,
ocrelizumab, as well as the fully … relative lack of early exposure to common pathogens during …
ocrelizumab, as well as the fully … relative lack of early exposure to common pathogens during …
代谢途径可作为进行性多发性硬化的可能治疗靶点
RM Heidker, MR Emerson, SM LeVine - 中国神经再生研究(英文版), 2017 - sjzsyj.com.cn
… These therapies can slow the development of disability and as a … Ocrelizumab, which is
approved for use in PPMS patients, … of progressive multiple sclerosis are less well understood. …
approved for use in PPMS patients, … of progressive multiple sclerosis are less well understood. …
奥法妥木单抗治疗视神经脊髓炎谱系疾病疗效分析
张锐， 陶永丽， 蒋晨阳， 刘凯， 许予明… - 中国现代神经疾病 … - journal11.magtechjournal.com
… ocrelizumab in OPERA Ⅰ/Ⅱ for the treatment of patients with relapsing multiple sclerosis[J]. …
ofatumumab with long ⁃ term exposure in relapsing multiple sclerosis [J]. Mult Scler J Exp …
ofatumumab with long ⁃ term exposure in relapsing multiple sclerosis [J]. Mult Scler J Exp …